Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study)
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Kim, Eun-JeongYin, Xiaoyan
Fontes, Joao D.
Magnani, Jared W.
Lubitz, Steven A.
McManus, David D.
Seshadri, Sudha
Vasan, Ramachandran S.
Ellinor, Patrick T.
Larson, Martin G.
Benjamin, Emelia J.
Rienstra, Michael
UMass Chan Affiliations
Department of Medicine, Division of Cardiovascular MedicineDepartment of Quantitative Health Sciences
Document Type
Journal ArticlePublication Date
2016-07-01Keywords
UMCCTS fundingepidemiology
atrial fibrillation
comorbidities
lone AF
Cardiology
Cardiovascular Diseases
Clinical Epidemiology
Epidemiology
Translational Medical Research
Metadata
Show full item recordAbstract
BACKGROUND: The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF. METHODS: We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality. RESULTS: Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF without comorbidities (47% women, mean age 71+/-12 years). AF without comorbidities had a prevalence of 1.7% of the entire cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137 individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P < .001) and total cardiovascular events (HR 0.66, 95% CI 0.55-0.80, P < .001) compared with typical AF. However, mortality (HR1.43, 95% CI 1.18-1.75, P < .001) and risk of total cardiovascular events (HR 1.73, 95% CI 1.39-2.16, P < .001) were higher than age-, sex-, and cohort-matched individuals without AF. CONCLUSIONS: The risk of cardiovascular outcomes and mortality among individuals with AF without comorbidities is lower than typical AF, but is significantly elevated compared with matched individuals without AF.Source
Am Heart J. 2016 Jul;177:138-44. doi: 10.1016/j.ahj.2016.03.023. Epub 2016 Apr 30. Link to article on publisher's siteDOI
10.1016/j.ahj.2016.03.023Permanent Link to this Item
http://hdl.handle.net/20.500.14038/50508PubMed ID
27297859Related Resources
Link to Article in PubMedRights
Open Access funded by VSNU. Under a Creative Commons license, http://creativecommons.org/licenses/by/4.0/.Distribution License
http://creativecommons.org/licenses/by/4.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.ahj.2016.03.023
Scopus Count
Except where otherwise noted, this item's license is described as Open Access funded by VSNU. Under a Creative Commons license, http://creativecommons.org/licenses/by/4.0/.